PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

Loflus Jr, E. V.; Harewood, G. C.; Loflus, C. G.; Tremaine, W. J.; Harmsen, W. S.; Zinsmeister, A. R.; Jewell, D. A.; Sondborn, W. J.
January 2005
Gut;Jan2005, Vol. 54 Issue 1, p91
Academic Journal
Background: inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD) may have a high prevalence of rectal sparing, backwash ileitis, and colorectal neoplasia. Aims: To describe the clinical features and outcomes of PSC-IBD and compare these to a group of chronic ulcerative colitis (CUC) patients. Methods: The medical records of all patients with PSC-IBD evaluated at the Mayo Clinic Rochester between 1987 and 1992 were abstracted for information on endoscopic and histological features, colorectal neopkisia, surgery, and other clinical outcomes. Patients referred for colorectal neoplasia and those who did not undergo colonoscopy with biopsies were excluded. A control group of CUC patients matched for sex, duration of IBD at first clinic visit, and calendar year of first clinic visit was identified, and similar information was abstracted. Results: Seventy one PSC-IBD patients and 142 CUC patients without PSC were identified. Rectal sparing and backwash ileitis were more common in the PSC-IBD group (52% and 51%, respectively) than in controls (6% and 7%, respectively). Overall, colorectal neoplasia developed in 18 cases and 15 controls, including 11 cancers (seven cases and four controls). An increased risk of colorectal neoplasia or death was not detected in a matched analysis. Although the cumulative incidence of colorectal neoplasia was higher in cases (33%) than in controls (13%) at five years, this was of borderline statistical significance (p =0.054, unmatched log rank test). Overall survival from first clinic visit was significantly worse among cases (79% v 97%) at five years (p<0.001, unmatched log rank test). Conclusion: PSC-IBD is frequently characterised by rectal sparing and backwash ileitis. Colorectal neoplasia develops in a substantial fraction and overall survival is worse. PSC-IBD may represent a distinct IBD phenotype.


Related Articles

  • Immune responses triggering colitis and colitis-associated carcinoma. Kesselring, Rebecca; Fichtner-Feigl, Stefan // Langenbeck's Archives of Surgery;Apr2012, Vol. 397 Issue 4, p527 

    Inflammatory bowel diseases compromise of two forms of chronic intestinal inflammatory disorders: Crohn's disease and ulcerative colitis. Both forms of inflammatory bowel disease result from inappropriate inflammatory responses to the intestinal microbiota, but have different underlying immune...

  • Inflammatory Bowel Disorders.  // Current Medical Literature: Gastroenterology;2011, Vol. 30 Issue 1, p21 

    The article discusses various research that explored the different aspects of inflammatory bowel disorders. One of the studies dealt with the changes in surgical resection rates and medical treatments for Crohn's disease. Another research focused on the association of pre-operative management...

  • Information management and informatics: need for a modern pathology service. Jones, Rick; O'Connor, John // Annals of Clinical Biochemistry;May2004, Vol. 41 Issue 3, p183 

    Requirements for information technology in pathology now extend well beyond the provision of purely analytical data. With the aim of achieving seamless integration of laboratory data into the total clinical pathway, 'informatics' - the art and science of turning data into useful information - is...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Inflammatory bowel disease posters.  // Gut;Apr2005 Supplement 2, Vol. 54, pA89 

    The article presents information on abstracts related to inflammatory bowel disease. An abstract presents information on the faecal calprotectin in the management of IBD and in the assessment of patients with LBS. Calprotectin is a neutrophil derived protein that is stable in stool. It shows...

  • Neuroinflammation in inflammatory bowel disease. Lakhan, Shaheen E.; Kirchgessner, Annette // Journal of Neuroinflammation;2010, Vol. 7, p37 

    Inflammatory bowel disease is a chronic intestinal inflammatory condition, the pathology of which is incompletely understood. Gut inflammation causes significant changes in neurally controlled gut functions including cramping, abdominal pain, fecal urgency, and explosive diarrhea. These symptoms...

  • Growth Impairment in Inflammatory Bowel Disease. Sherlock, Mary; Griffiths, Anne M. // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2008, Vol. 2 Issue 2, p41 

    The article presents information on the prevalence of growth impairment in pediatric inflammatory bowel disease (IBD). It explores the patterns of growth and pubertal progression in young patients with IBD. It explains the standardized monitoring and assessment of growth. It discusses the...

  • Inflammatory Bowel Disease Part II: Crohn's Disease - Pathophysiology and Conventional and Alternative Treatment Options. Head, Kathleen; Jurenka, Julie // Alternative Medicine Review;Dec2004, Vol. 9 Issue 4, p360 

    Crohn's disease, a subcategory of inflammatory bowel disease, contributes to significant morbidity, particularly in industrialized nations. It can affect people of any age, but is more commonly diagnosed in adolescence and young adulthood. Inflammation and ulceration occur primarily in the...

  • Inflammatory Bowel Disease: Its Present and Its Future. Kirsner, Joseph B. // American Journal of Gastroenterology;Nov1989, Vol. 84 Issue 11, p1358 

    Discusses the developments in the treatment of inflammatory bowel disease (IBD) as of 2005. Experiment done to determine the treatment for IBD; Pathogenesis of IBD; Microbial cause of IBD.


Read the Article


Sign out of this library

Other Topics